A new trading day began on Friday, with Candel Therapeutics Inc (NASDAQ: CADL) stock price down -4.75% from the previous day of trading, before settling in for the closing price of $12.21. CADL’s price has ranged from $1.34 to $14.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.00% over the last five years. Meanwhile, its annual earnings per share averaged -4.53%. With a float of $32.45 million, this company’s outstanding shares have now reached $44.48 million.
The firm has a total of 42 workers. Let’s measure their productivity. In terms of profitability, gross margin is 54.28%, operating margin of -2001.58%, and the pretax margin is -2939.13%.
Candel Therapeutics Inc (CADL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Candel Therapeutics Inc is 27.04%, while institutional ownership is 36.04%. The most recent insider transaction that took place on Jan 15 ’25, was worth 97,783. In this transaction Chief Scientific Officer of this company sold 13,534 shares at a rate of $7.22, taking the stock ownership to the 110,673 shares. Before that another transaction happened on Jan 15 ’25, when Company’s Chief Technology Officer sold 14,322 for $7.22, making the entire transaction worth $103,476. This insider now owns 96,790 shares in total.
Candel Therapeutics Inc (CADL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -4.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.88% during the next five years compared to -46.75% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Here are Candel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -1.02 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Analysing the last 5-days average volume posted by the [Candel Therapeutics Inc, CADL], we can find that recorded value of 2.33 million was better than the volume posted last year of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 74.57%. Additionally, its Average True Range was 0.91.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 72.54%, which indicates a significant increase from 70.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.12% in the past 14 days, which was lower than the 152.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.04, while its 200-day Moving Average is $6.90. Now, the first resistance to watch is $12.06. This is followed by the second major resistance level at $12.48. The third major resistance level sits at $12.81. If the price goes on to break the first support level at $11.30, it is likely to go to the next support level at $10.97. Now, if the price goes above the second support level, the third support stands at $10.55.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
With a market capitalization of 517.25 million, the company has a total of 32,476K Shares Outstanding. Currently, annual sales are 0 K while annual income is -37,940 K. The company’s previous quarter sales were 0 K while its latest quarter income was -10,650 K.
